A UK Time Trends Analysis of Dual Antiplatelet Therapy Use and Bleeding in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

被引：0
|
作者：
Mahadevan, Kalaivani [1 ]
Harris, Jessica [2 ]
Pufulete, Maria [2 ]
Johnson, Tom [1 ]
机构：
[1] Bristol Heart Inst, Bristol, Avon, England
[2] Univ Bristol, Bristol, Avon, England
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 74卷 / 13期
关键词：
D O I：
10.1016/j.jacc.2019.08.486
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
TCT-396
引用
收藏
页码：B392 / B392
页数：1
相关论文
共 50 条
  • [31] Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention
    Mohammad Alkhalil
    Vladimír Džavík
    Deepak L. Bhatt
    Roxana Mehran
    Shamir R. Mehta
    Current Cardiology Reports, 2022, 24 : 277 - 293
  • [32] Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention
    Bhatty, Shaun
    Ali, Asghar
    Shetty, Ranjith
    Sumption, Kevin F.
    Cowley, Michael J.
    Jovin, Ion S.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2014, 12 (04) : 463 - 474
  • [33] Dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention: with what and for how long?
    Darius, Harald
    INTERNIST, 2021, 62 (11): : 1243 - 1252
  • [34] Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention
    Alkhalil, Mohammad
    Dzavik, Vladimir
    Bhatt, Deepak L.
    Mehran, Roxana
    Mehta, Shamir R.
    CURRENT CARDIOLOGY REPORTS, 2022, 24 (03) : 277 - 293
  • [35] Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy
    Hamilos, Michalis
    Petousis, Stylianos
    Xanthopoulou, Ioanna
    Goudevenos, John
    Kanakakis, John
    Sitafidis, George
    Vavouranakis, Manolis
    Skalidis, Emmanuel
    Kochiadakis, George
    Lekakis, John
    Vardas, Panos E.
    Alexopoulos, Dimitrios
    CORONARY ARTERY DISEASE, 2018, 29 (01) : 53 - 59
  • [36] Outcomes of patients with cerebral microbleeds undergoing percutaneous coronary intervention and dual antiplatelet therapy
    Fujino, Masashi
    Noguchi, Teruo
    Torii-Yoshimura, Takako
    Okuno, Yoshinori
    Morita, Yoshiaki
    Nishimura, Kunihiro
    Otsuka, Fumiyuki
    Kataoka, Yu
    Asaumi, Yasuhide
    Yamagami, Hiroshi
    Yasuda, Satoshi
    HEART AND VESSELS, 2024, 39 (09) : 763 - 770
  • [37] β1-blockers in the reduction of bleeding risk in patients prescribed with potent dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention
    Zhang, Shizhao
    Wu, Yangxun
    Lv, Chao
    Liu, Haiping
    Wang, Yuyan
    Dong, Lisha
    Liu, Yuqi
    Wang, Shengshu
    Jia, Jianjun
    Yin, Tong
    HELLENIC JOURNAL OF CARDIOLOGY, 2024, 79 : 15 - 24
  • [38] PREDICT CLINICAL AND BLEEDING RISKS ON DECISION OF DURATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGONE PERCUTANEOUS CORONARY INTERVENTION
    Park, Jin Sup
    Cha, Kwang Soo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 43 - 43
  • [39] Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: Balancing efficacy and bleeding risk
    Spinler, Sarah A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (15) : S7 - S17
  • [40] THE OPTIMAL DURATION OF DUAL ANTIPLATELET THERAPY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS
    Ma Yi-Tong
    Yu Zi-Xiang
    Yang Yi-Ning
    Bayinsilema, Ba
    HEART, 2013, 99 : A48 - A48
12345